DXD Monoclonal Antibody

Code CSB-MA996977I1m
Size US$329
Order now
Image
  • DXD antibody on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 90%.
  • The Binding Activity of ADC-1(DXD) with Anti-DXD antibody
    Activity: Measured by its binding ability in a functional ELISA. Immobilized ADC-1(DXD) at 2 μg/mL can bind Anti-DXD antibody, the EC50 is 1.840 to 2.253 ng/mL.
  • The Binding Activity of ADC-2(DXD) with Anti-DXD antibody
    Activity: Measured by its binding ability in a functional ELISA. Immobilized ADC-2(DXD) at 2 μg/mL can bind Anti-DXD antibody, the EC50 is 2.365 to 2.835 ng/mL.
  • The Binding Activity of T-DXd(DS-8201) with Anti-DXD antibody
    Activity: Measured by its binding ability in a functional ELISA. Immobilized T-DXd(DS-8201) at 2 μg/mL can bind Anti-DXD antibody, the EC50 is 2.225 to 2.851 ng/mL.
  • The purity of Mouse Anti-DXD Antibody is more than 90% by SEC-MALS.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Names
DXD
Alternative Names
Exatecan derivative
Immunogen
DXD-BSA conjugate
Conjugate
Non-conjugated
Clonality
Monoclonal
Isotype
IgG2a
Clone No.
8D12C11
Purification Method
Affinity-chromatography
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form
Liquid
Tested Applications
ELISA
Protocols
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

The DXD monoclonal antibody is created using the hybridoma technique. Immunizing a mouse with DXD-BSA induces antibody production by B cells. B cells are extracted from the mouse and then fused with myeloma cells to form hybridomas, from which DXD-specific antibody-producing ones are screened. Selected hybridomas are cultured to generate DXD monoclonal antibodies, which are harvested and subjected to affinity chromatography purification. The purity of the antibody exceeds 90% by SEC-MALS. The antibody's activity has been validated in different functional ELISA, showing the EC50 of 1.840 to 2.253 ng/mL, 2.365 to 2.835 ng/mL, 2.225 to 2.851 ng/mL with ADC-1 (DXD), ADC-2 (DXD), T-DXd (DS-8201), respectively. This DXD monoclonal antibody is a potent tool for DXD-based ADC research, especially for positive reference of DXD-ADC preclinical/clinical immunogenicity, PK analysis, and qualitative detection of DAR value, helping to evaluate and control the efficacy and safety of DXD-ADC drugs.

The Exatecan derivative DXD (deruxtecan) is a cytotoxic payload used in the DXD-ADC (antibody–drug conjugate) technology, an innovative strategy in the field of targeted drug delivery particularly for cancer therapy. DXD-ADC is directed to targeted tumor cells via antibody-tumor cell-sepcific antigen interaction. After that, ADC undergoes internalization and subsequent processing, leading to the release of the cytotoxic DXD. DXD inhibits topoisomerase I (TOP1) activity and leads to the apoptosis of targeted cancer cells. DXD shows 10-fold higher DNA TOP1 activity inhibitory potency than the active metabolite of irinotecan SN-38. Due to its high cell membrane permeability, DXD exerts a bystander antitumor effect, also providing efficient killing of heterogeneous tumor cells. DXD can reduce cross-resistance, has good water solubility, and can form a stable high-DAR (drug-to-antibody ratio) value in ADC for each target. DXD also has a relatively short systemic half-life in the blood and can be excreted faster outside the body, which helps reduce the risk of adverse reactions.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*